CMN Weekly (1 July 2022) - Your Weekly CRISPR...
Jul. 1, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Viacyte
Main focus: Stem cell engineering for treatment of diabetes
Company stage: Clinical
Diseases: Type 1 and 2 diabetes
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: San Diego, CA, USA
Website: https://viacyte.com/
Pipeline: https://viacyte.com/pipeline/
Partners: CRISPR Therapeutics
Viacyte is developing engineered stem cells in order to treat diabetes. The company has an ongoing collaboration with CRISPR Therapeutics, for which the companies seek to develop a next generation stem cell product for all type 1 diabetes and insulin-requiring type 2 diabetes patients. The programme is currently in a research phase.
